Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2021-01, Vol.35 (1), p.169-176 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 176 |
|---|---|
| container_issue | 1 |
| container_start_page | 169 |
| container_title | Leukemia |
| container_volume | 35 |
| creator | Al-Sawaf, O. Robrecht, S. Bahlo, J. Fink, A. M. Cramer, P. v Tresckow, J. Lange, E. Kiehl, M. Dreyling, M. Ritgen, M. Dürig, J. Tausch, E. Schneider, C. Stilgenbauer, S. Wendtner, C. M. Fischer, K. Goede Hallek, M. Eichhorst, B. |
| description | Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1–69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09–3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT. |
| doi_str_mv | 10.1038/s41375-020-0797-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2475611444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650172564</galeid><sourcerecordid>A650172564</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-8d42d4066680acbd0ec71b01e12a16884e3ab5cc04c1f5eb1c0790d9342959303</originalsourceid><addsrcrecordid>eNp1kcGO1iAQx4nRuJ-rD-DFkJiY3UMVKND2uPmi1eRLTFw9E0qnW9a2VKDJ9uYbePEJfRJpuurJ0wDzm_8M80foOSWvKcnLN4HTvBAZYSQjRVVkdw_QgfJCZkII-hAdSFkWmawYP0NPQrglZEvKx-gsZ4zklNMD-vHJmj6Cx9HrKXTOjzpaN2E7YdN7N1mDh3Wce2fWuJ1h-Qqj1fjieDpd_vr-U-PZuQFarCc9rMEG7DpcQ5KZcELwdVzaFdfeLTO-qNPLdX2JuyQc8WAnSG1BxxHSNXqrh_AUPepSgGf38Rx9eff28_F9dvpYfzhenTLDSR6zsuWs5URKWRJtmpaAKWhDKFCmqSxLDrluhDGEG9oJaKhJCyJtlXNWiSon-Tl6uevO3n1bIER16xaf_hAU44WQlHLOE_Vqp270AKoHPcQ-uGHZVhTUlRSEFkzIDaQ7aLwLwUOnZm9H7VdFidq8UrtXKnmlNq_UXap5cT_C0ozQ_q34Y04C2A6ElJpuwP-b8f-qvwERgZ_d</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475611444</pqid></control><display><type>article</type><title>Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Al-Sawaf, O. ; Robrecht, S. ; Bahlo, J. ; Fink, A. M. ; Cramer, P. ; v Tresckow, J. ; Lange, E. ; Kiehl, M. ; Dreyling, M. ; Ritgen, M. ; Dürig, J. ; Tausch, E. ; Schneider, C. ; Stilgenbauer, S. ; Wendtner, C. M. ; Fischer, K. ; Goede ; Hallek, M. ; Eichhorst, B.</creator><creatorcontrib>Al-Sawaf, O. ; Robrecht, S. ; Bahlo, J. ; Fink, A. M. ; Cramer, P. ; v Tresckow, J. ; Lange, E. ; Kiehl, M. ; Dreyling, M. ; Ritgen, M. ; Dürig, J. ; Tausch, E. ; Schneider, C. ; Stilgenbauer, S. ; Wendtner, C. M. ; Fischer, K. ; Goede ; Hallek, M. ; Eichhorst, B.</creatorcontrib><description>Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1–69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09–3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/s41375-020-0797-x</identifier><identifier>PMID: 32203141</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/1541/1990/283/1895 ; 692/699/67/1990/291/1621/1915 ; Adult ; Aged ; Aged, 80 and over ; Autografts ; B-cell lymphoma ; Biopsy ; Cancer ; Cancer Research ; Care and treatment ; Cell Transformation, Neoplastic - genetics ; Chronic lymphocytic leukemia ; Clinical trials ; Critical Care Medicine ; Development and progression ; Diagnosis ; Disease Progression ; Evaluation ; Female ; Genetic transformation ; Genetic Variation ; Germany ; Hematology ; Hodgkin's lymphoma ; Humans ; Intensive ; Internal Medicine ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - genetics ; Leukemia, Lymphocytic, Chronic, B-Cell - pathology ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Lymphatic leukemia ; Lymphocytes B ; Lymphoma ; Lymphoma - etiology ; Lymphoma - mortality ; Lymphoma - pathology ; Lymphoma - therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Oncology ; Oncology, Experimental ; Prognosis ; Stem cell transplantation ; Stem cells ; Survival Analysis ; Time Factors ; Transplantation ; Young Adult</subject><ispartof>Leukemia, 2021-01, Vol.35 (1), p.169-176</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-8d42d4066680acbd0ec71b01e12a16884e3ab5cc04c1f5eb1c0790d9342959303</citedby><cites>FETCH-LOGICAL-c403t-8d42d4066680acbd0ec71b01e12a16884e3ab5cc04c1f5eb1c0790d9342959303</cites><orcidid>0000-0001-9895-0570</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41375-020-0797-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41375-020-0797-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32203141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Sawaf, O.</creatorcontrib><creatorcontrib>Robrecht, S.</creatorcontrib><creatorcontrib>Bahlo, J.</creatorcontrib><creatorcontrib>Fink, A. M.</creatorcontrib><creatorcontrib>Cramer, P.</creatorcontrib><creatorcontrib>v Tresckow, J.</creatorcontrib><creatorcontrib>Lange, E.</creatorcontrib><creatorcontrib>Kiehl, M.</creatorcontrib><creatorcontrib>Dreyling, M.</creatorcontrib><creatorcontrib>Ritgen, M.</creatorcontrib><creatorcontrib>Dürig, J.</creatorcontrib><creatorcontrib>Tausch, E.</creatorcontrib><creatorcontrib>Schneider, C.</creatorcontrib><creatorcontrib>Stilgenbauer, S.</creatorcontrib><creatorcontrib>Wendtner, C. M.</creatorcontrib><creatorcontrib>Fischer, K.</creatorcontrib><creatorcontrib>Goede</creatorcontrib><creatorcontrib>Hallek, M.</creatorcontrib><creatorcontrib>Eichhorst, B.</creatorcontrib><title>Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1–69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09–3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.</description><subject>692/699/1541/1990/283/1895</subject><subject>692/699/67/1990/291/1621/1915</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Autografts</subject><subject>B-cell lymphoma</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>Chronic lymphocytic leukemia</subject><subject>Clinical trials</subject><subject>Critical Care Medicine</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Evaluation</subject><subject>Female</subject><subject>Genetic transformation</subject><subject>Genetic Variation</subject><subject>Germany</subject><subject>Hematology</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - pathology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma - etiology</subject><subject>Lymphoma - mortality</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Prognosis</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Survival Analysis</subject><subject>Time Factors</subject><subject>Transplantation</subject><subject>Young Adult</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kcGO1iAQx4nRuJ-rD-DFkJiY3UMVKND2uPmi1eRLTFw9E0qnW9a2VKDJ9uYbePEJfRJpuurJ0wDzm_8M80foOSWvKcnLN4HTvBAZYSQjRVVkdw_QgfJCZkII-hAdSFkWmawYP0NPQrglZEvKx-gsZ4zklNMD-vHJmj6Cx9HrKXTOjzpaN2E7YdN7N1mDh3Wce2fWuJ1h-Qqj1fjieDpd_vr-U-PZuQFarCc9rMEG7DpcQ5KZcELwdVzaFdfeLTO-qNPLdX2JuyQc8WAnSG1BxxHSNXqrh_AUPepSgGf38Rx9eff28_F9dvpYfzhenTLDSR6zsuWs5URKWRJtmpaAKWhDKFCmqSxLDrluhDGEG9oJaKhJCyJtlXNWiSon-Tl6uevO3n1bIER16xaf_hAU44WQlHLOE_Vqp270AKoHPcQ-uGHZVhTUlRSEFkzIDaQ7aLwLwUOnZm9H7VdFidq8UrtXKnmlNq_UXap5cT_C0ozQ_q34Y04C2A6ElJpuwP-b8f-qvwERgZ_d</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Al-Sawaf, O.</creator><creator>Robrecht, S.</creator><creator>Bahlo, J.</creator><creator>Fink, A. M.</creator><creator>Cramer, P.</creator><creator>v Tresckow, J.</creator><creator>Lange, E.</creator><creator>Kiehl, M.</creator><creator>Dreyling, M.</creator><creator>Ritgen, M.</creator><creator>Dürig, J.</creator><creator>Tausch, E.</creator><creator>Schneider, C.</creator><creator>Stilgenbauer, S.</creator><creator>Wendtner, C. M.</creator><creator>Fischer, K.</creator><creator>Goede</creator><creator>Hallek, M.</creator><creator>Eichhorst, B.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-9895-0570</orcidid></search><sort><creationdate>20210101</creationdate><title>Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials</title><author>Al-Sawaf, O. ; Robrecht, S. ; Bahlo, J. ; Fink, A. M. ; Cramer, P. ; v Tresckow, J. ; Lange, E. ; Kiehl, M. ; Dreyling, M. ; Ritgen, M. ; Dürig, J. ; Tausch, E. ; Schneider, C. ; Stilgenbauer, S. ; Wendtner, C. M. ; Fischer, K. ; Goede ; Hallek, M. ; Eichhorst, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-8d42d4066680acbd0ec71b01e12a16884e3ab5cc04c1f5eb1c0790d9342959303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/699/1541/1990/283/1895</topic><topic>692/699/67/1990/291/1621/1915</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Autografts</topic><topic>B-cell lymphoma</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>Chronic lymphocytic leukemia</topic><topic>Clinical trials</topic><topic>Critical Care Medicine</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Evaluation</topic><topic>Female</topic><topic>Genetic transformation</topic><topic>Genetic Variation</topic><topic>Germany</topic><topic>Hematology</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - pathology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma - etiology</topic><topic>Lymphoma - mortality</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Prognosis</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Survival Analysis</topic><topic>Time Factors</topic><topic>Transplantation</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Sawaf, O.</creatorcontrib><creatorcontrib>Robrecht, S.</creatorcontrib><creatorcontrib>Bahlo, J.</creatorcontrib><creatorcontrib>Fink, A. M.</creatorcontrib><creatorcontrib>Cramer, P.</creatorcontrib><creatorcontrib>v Tresckow, J.</creatorcontrib><creatorcontrib>Lange, E.</creatorcontrib><creatorcontrib>Kiehl, M.</creatorcontrib><creatorcontrib>Dreyling, M.</creatorcontrib><creatorcontrib>Ritgen, M.</creatorcontrib><creatorcontrib>Dürig, J.</creatorcontrib><creatorcontrib>Tausch, E.</creatorcontrib><creatorcontrib>Schneider, C.</creatorcontrib><creatorcontrib>Stilgenbauer, S.</creatorcontrib><creatorcontrib>Wendtner, C. M.</creatorcontrib><creatorcontrib>Fischer, K.</creatorcontrib><creatorcontrib>Goede</creatorcontrib><creatorcontrib>Hallek, M.</creatorcontrib><creatorcontrib>Eichhorst, B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Sawaf, O.</au><au>Robrecht, S.</au><au>Bahlo, J.</au><au>Fink, A. M.</au><au>Cramer, P.</au><au>v Tresckow, J.</au><au>Lange, E.</au><au>Kiehl, M.</au><au>Dreyling, M.</au><au>Ritgen, M.</au><au>Dürig, J.</au><au>Tausch, E.</au><au>Schneider, C.</au><au>Stilgenbauer, S.</au><au>Wendtner, C. M.</au><au>Fischer, K.</au><au>Goede</au><au>Hallek, M.</au><au>Eichhorst, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>35</volume><issue>1</issue><spage>169</spage><epage>176</epage><pages>169-176</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><abstract>Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1–69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09–3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32203141</pmid><doi>10.1038/s41375-020-0797-x</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9895-0570</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2021-01, Vol.35 (1), p.169-176 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_journals_2475611444 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 692/699/1541/1990/283/1895 692/699/67/1990/291/1621/1915 Adult Aged Aged, 80 and over Autografts B-cell lymphoma Biopsy Cancer Cancer Research Care and treatment Cell Transformation, Neoplastic - genetics Chronic lymphocytic leukemia Clinical trials Critical Care Medicine Development and progression Diagnosis Disease Progression Evaluation Female Genetic transformation Genetic Variation Germany Hematology Hodgkin's lymphoma Humans Intensive Internal Medicine Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - pathology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Lymphatic leukemia Lymphocytes B Lymphoma Lymphoma - etiology Lymphoma - mortality Lymphoma - pathology Lymphoma - therapy Male Medicine Medicine & Public Health Middle Aged Neoplasm Grading Neoplasm Staging Oncology Oncology, Experimental Prognosis Stem cell transplantation Stem cells Survival Analysis Time Factors Transplantation Young Adult |
| title | Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A33%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Richter%20transformation%20in%20chronic%20lymphocytic%20leukemia%20(CLL)%E2%80%94a%20pooled%20analysis%20of%20German%20CLL%20Study%20Group%20(GCLLSG)%20front%20line%20treatment%20trials&rft.jtitle=Leukemia&rft.au=Al-Sawaf,%20O.&rft.date=2021-01-01&rft.volume=35&rft.issue=1&rft.spage=169&rft.epage=176&rft.pages=169-176&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/s41375-020-0797-x&rft_dat=%3Cgale_proqu%3EA650172564%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2475611444&rft_id=info:pmid/32203141&rft_galeid=A650172564&rfr_iscdi=true |